

Ref. No: 305270921
From: Commercial
Date: 27/09/21
Subject: Biologic medications in gastroenterology

REQUEST

I am analysing the usage of new biologic medications in gastroenterology. I would greatly appreciate if you could answer the following two questions.

Q1. How many patients were treated in August 2021 (or latest available month) by the gastroenterology department with the following drugs:

- Adalimumab (any brand or biosimilar) 95
- Infliximab (any brand or biosimilar) 105
- Ustekinumab (Stelara) 39
- Vedolizumab (Entyvio) 31
- Tofacitinib (Xeljanz) *<5

Please note *<5 has been added where the number of patients is 5 or less, this information has been redacted to protect patient confidentiality and to ensure that patients can not be identified.

- Filgotinib (Jyseleca) 0

Q2. How many patients were treated in August 2021 (or latest available month) for Crohn's Disease ONLY with the following drugs:

- Adalimumab (any brand or biosimilar) 52
- Infliximab (any brand or biosimilar) 54
- Ustekinumab (Stelara) 35
- Vedolizumab (Entyvio) 9

RESPONSE

The numbers for each are listed above.